No Data
No Data
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71
Vera Therapeutics Analyst Ratings
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $71
Vera Therapeutics | 10-K: FY2024 Annual Report